# Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

> **NCT04873869** · PHASE2 · TERMINATED · sponsor: **Neurocrine Biosciences** · enrollment: 8 (actual)

## Conditions studied

- SCN8A Developmental and Epileptic Encephalopathy Syndrome

## Interventions

- **DRUG:** NBI-921352
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04873869
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-31
- **Primary completion:** 2023-03-17
- **Final completion:** 2023-03-17
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** This study was prematurely terminated due to sponsor decision.
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04873869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04873869, "Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04873869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*